Clinical trial
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
NCT04480372
Study timeline
Study start (actual)2021-03-17Date precision: day
Registry last updated2024-07-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Malignant Pleural Mesotheliomaunresolved
Non-small Cell Lung Cancerunresolved
Interventions
GemcitabineDRUG · verified · RxNorm: gemcitabine
AtezolizumabDRUG · verified · RxNorm: atezolizumab
Sponsors & collaborators
Swiss Cancer Institutelead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04480372 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.